Skip to main content

NEW YORK (

TheStreet

) -- U.S. stock futures were flat early Monday ahead of the latest meeting of "Merkozy" -- German Chancellor Angela Merkel and French President Nicolas Sarkozy are meeting to discuss ways to boost growth as debt fears in the eurozone once again linger.

European stocks were higher, getting a boost from a rise in German exports.

Asian stocks finished higher Monday. The benchmark Shanghai Composite Index gained 2.9% to 2,225.89, while the Hang Seng in Hong Kong rose 1.5%. Markets in Japan were closed.

U.S. stocks finished last week, the first trading week of 2012, with solid gains. The

Dow Jones Industrial Average

on Friday settled down 56 points, or 0.5%, to 12,360 but posted a gain of more than 1% for the week.

The

S&P 500

dropped 3 points, or 0.3%, to 1,278, putting the index 1.6% ahead for the week. The

Nasdaq

tacked on 4 points, or 0.2%, to 2,674 on Friday, and posted a 2.7% gain for the week.

The economic calendar in the U.S. includes the Conference Board's employment trend index for December at 10 a.m. EST. The

Federal Reserve

TheStreet Recommends

is scheduled to issue consumer credit data at 3 p.m.

Alcoa

(AA) - Get Alcoa Corporation Report

posts results after the closing bell Monday, marking the unofficial start to the earnings season.

The aluminum maker last week said its global smelting capacity will be reduced by 12% after the closure of certain plants. Alcoa said it would record fourth-quarter restructuring charges of $155 million to $165 million.

Analysts' expectations on Alcoa's results vary from a loss of 5 cents a share to a profit of 1 cent.

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

plans to acquire

Inhibitex

(INHX)

for $2.5 billion.

Bristol-Myers' all-cash tender offer values Inhibitex at $26 a share

, or more than two-and-a-half times the company's closing stock price on Friday of $9.87.

For all that cash, Bristol-Myers gains control of Inhibitex's INX-189, a pill in phase II studies which has the potential to become a component in the first all-oral therapies against hepatitis C.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here:

Joseph Woelfel

>To submit a news tip, send an email to:

tips@thestreet.com

.